Feedback form - Please send us Feedback

Institute of NeuroImmune Pharmacology

Vision of INIP


In Congruence with Worlds Ahead Strategic Plan of FIU/ HWCOM, and NIH Road map INIP will engage in:

  • State-of-the-art and translational research, creative activity.
  • High quality teaching
  • Training and collaborative engagements.


  1. Provide academic leadership in Immunology/NeuroImmune pharmacology in the college of medicine and FIU
  2. Develop, foster and sustain a program of translational research (bench to bedside) and training in Immunology, Neuro-Immune pharmacology of Drug abuse ,HIV/ CNS diseases and cosmetic medicine
  3. Develop novel drug delivery technologies to treat HIV, drug addiction and various CNS diseases.
  4. Build bridges between research and training activities at the graduate, undergraduate and post doctoral levels for PhD,. MD and M.P.H scientists and practicing immunologists.
  5. To nurture /mentor junior researchers to become independent NIH funded investigators.
  6. To establish academic and Industry collaboration with in US and abroad.

Current Objectives

  • Develop an in vitro model system by which the HIV drugs can be specifically targeted to the brain using magnetic Nanotechnology approach to cure Neuro-AIDS.
  • Formulate Nano silicone particles for constructing immunologically naïve breast implants.
  • Differential neuro-AIDS prevalent in different HIV-1 Clades infections and to evaluate the exacerbating effects of drug abuse in HIV Clade included differential neuropathogenesis.
  • To study the behavioral aspects of animals treated with magnetic nanoparticles tagged with opioid receptors antagonists in the drug abuse research area.
  • Magneto-Electric Nano-particles for Non-invasive Brain stimulation

Future Objectives

  • Preparation of various sizes of nicotine nanoparticles to construct next generation of nicotine patches for clinical use.
  • Develop and target a specific drug targeting the brain to treat specific brain tumors
  • Develop treatment programs using Novel Personalized Nanomedicine paradigms to treat Parkinson’s disease and Alzheimer’s disease.